Licensing status

Publication and contact information

Disease models

Mouse model for partner and localizer of Brca2 (Palb2)-deficient breast cancer

A mouse model for Palb2-deficient breast cancer could be useful for evaluating new therapies. Mutations in PALB2 are associated with increased risk of breast cancer, but genetically engineered mouse models to study the gene's function were unavailable because Palb2 deletion causes embryonic lethality. In the new model, mice were engineered to carry Palb2 that could be conditionally inactivated. In this model, Palb2 was shown to synergize with p53 to suppress breast tumor formation. Next steps could include using the mouse model to evaluate therapies to treat PALB2 mutant breast cancer.

SciBX 6(22); doi:10.1038/scibx.2013.558
Published online June 6, 2013

Patent and licensing status unavailable

Bowman-Colin, C. et al.
Proc. Natl. Acad. Sci. USA
; published online May 8, 2013;
Contact: David M. Livingston,
Dana-Farber Cancer Institute, Boston, Mass.
Contact: Chryssa Kanellopoulou, National Institutes of Health, Bethesda, Md.